As have many other chemosensitive tumors, small-cell lung cancer (SCLC) has a well-documented chemotherapy dose-response relationship. However, a relationship between dose and survival has not yet been established. The effect of dose on survival should be examined in terms of both the dose used...
Liu, MD, discusses the effect of the FDA approval of atezolizumab on the development of other chemoimmunotherapy regimens and ongoing efforts to expand and individualize treatment options in small cell lung cancer. Stephen V. Liu, MD The addition of immunotherapy to carboplatin and etoposide improv...
Chemo-radioresistance of small cell lung cancer cell lines derived from untreated primary tumors obtained by diagnostic bronchofiberscopy : Tanio Y, Watanabe M, Inoue T et al. Third Department of Internal Medicine, Osaka University Medical School, 1-1-50 Fukushima, Fukushima-ku, Osaka 553. Jpn ...
Primary, adaptive, and acquired resistance to cancer immunotherapy Cell, 168 (4) (2017), pp. 707-723 Google Scholar 47 L. Bonanno, A. Pavan, M.V. Dieci, et al. The role of immune microenvironment in small-cell lung cancer: distribution of PD-L1 expression and prognostic role of FOXP3...
Circulating tumor cells from patients with small-cell lung cancer can form tumors in mice, and their derived explants recapitulate the patients' response to chemotherapy. Small-cell lung cancer (SCLC), an aggressive neuroendocrine tumor with early dissem
Small cell lung cancer (SCLC) lacks effective treatments to overcome chemoresistance. Here we established multiple human chemoresistant xenograft models through long-term intermittent chemotherapy, mimicking clinically relevant therapeutic settings. We show that chemoresistant SCLC undergoes metabolic reprogramming...
Combined small-cell carcinoma Both include many types of cells that grow and spread in different ways. They’re named according to what the cells look like under a microscope. Small-cell lung cancer differs from non-small-cell lung cancer in some key ways. Small-cell lung cancer: ...
Copyright © 2013 National Comprehensive Cancer Network, Inc., All Rights Reserved. STAGE Extensive stage (T any, N any, M1a/b; T3-4 due to multiple lung nodules) NCCN Guidelines Version 2.2013 Small Cell Lung Cancer NCCN Guidelines Index SCLC Table of Contents Discussion Extensive stage ...
Chemosensitization in non-small cell lung cancer cells by IKK inhibitor occurs via NF-kappaB and mitochondrial cytochrome c cascade. J. Cell Mol. Med.,... Zhang,Zhang,Wang,... 被引量: 0发表: 0年 Molecular pathways in the chemosensitization of cisplatin by quercetin in human head and neck...
Small-cell lung cancer rapidly develops resistance to standard-of-care therapy. Two papers now establish xenograft models derived from patient-derived circulating tumor cells and show that initially homogeneous, chemoresponsive tumors rapidly recur as heterogeneous drug-refractory disease. This is a ...